Loading stock data…
Immatics N.V. (IMTX)
$9.44-0.12 (-1.26%)
Market ClosedLast close Sep 8
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Immatics N.V. in the Healthcare sector is trading at $9.44 with a market capitalization of $1.4B. Wall Street consensus targets $17.63 (6 analysts), implying a +86.8% move over the next 12 months. The stock is currently 24% below its 52-week high of $12.41, remaining 5.7% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +86.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $7.61M↓ | $19.76M↑ | $5.19M↑ | $4.74M↓ | $18.58M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$66.06M↓ | -$38.88M↑ | -$54.63M↓ | -$53.13M↓ | -$35.37M |
| Net Income | -$57.81M↓ | -$35.70M↑ | -$50.55M↑ | -$70.35M↓ | -$39.85M |
Peer Comparison
JNJUNHPFE
Fundamentals
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies wi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.39B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-47.04%
Volume
Today's trading volume
699,513
Recent News
Immatics and 4 More Stocks See Action From Activist Investors
Activists also report to the SEC on Allot Communications, Genco Shipping & Trading, Aurinia Pharmaceuticals, and Turtle Beach.
Moderna’s Newfound War Chest Opens Door for 4 Strategic Acquisition Targets
Moderna's stock just surged in a way that transforms the company from a cash-burning vaccine maker into a serious acquirer, and four biotech targets already sit within striking range of its newly loaded war chest.
Analysts Are Updating Their Immatics N.V. (NASDAQ:IMTX) Estimates After Its First-Quarter Results
It's shaping up to be a tough period for Immatics N.V. ( NASDAQ:IMTX ), which a week ago released some disappointing...
Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates
Immatics (IMTX) delivered earnings and revenue surprises of -19.05% and -38.95%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth
Acadia's first-quarter earnings and revenues miss estimates despite 10% sales growth, driven by Nuplazid and Daybue demand.